Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2102 in HER2-Negative Recurrent/Metastatic Breast Cancer
NCT06452706Phase 2Recruiting
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQB2102 in breast cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
TQB2102
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06452706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452706.